For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
In the mouse, Tumor Necrosis Factor alpha (TNFa) is primarily produced as a homotrimeric 235 amino acid membrane- bound protein. The soluble mature homotrimeric form of 156 amino acids is then released by the metalloprotease TNFa converting enzyme. In humans, TNFa is produced by many cell types like macrophages, monocytes, neutrophils, T cells, and NK cells. It causes cytolysis and cytostasis of many tumor cell lines in vitro. Within hours of injection, TNFa leads to the destruction of small blood vessels within malignant tumors. Although TNFa inhibits the growth of endothelial cells in vitro, it is a potent promoter of angiogenesis in vivo. In contrast to chemotherapeutic drugs, TNFa specifically attacks malignant cells. Furthermore, TNFa is associated with autoimmune disorders, and antibodies directed against TNFa have proven useful.
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
|Assay Target Class||Cytokine|
|Experimental Type||In vitro|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||500 assay points|
Immunoassays are a mainstay for the quantification of a variety of biomolecular analytes in drug discovery, drug development, and life sciences research. AlphaLISA® proves advantageous to ELISAs, offering a novel, homogenous immunoassay technology that eliminates wash steps. Using the JANUS® Automated Workstation in combination with AlphaLISA provides a solution to easily preparing assays that can be tailored to the needs of the laboratory. Moreover, the JANUS workstation can be easily set-up to process different assay types in a multi-user, multi-assay environment, thus providing a flexible automation solution.
In this application note, we demonstrate the performance of the JANUS Workstation in automating four AlphaLISA cytokine assays: IL1b, TNFa, IL17, IFNg.
For the detection of three biomarkers in complex sample matrices, the AlphaLISA and Electrochemiluminescent (ECL) assay technologies were shown to have similar: Assay windows (linear dynamic range), Lower and upper detection limit, Intra-and inter-assay precision (lower % CV) The advantages of using AlphaLISA over ECL are: Shorter total assay duration No wash steps No shaking Lower sample volume requirement for equivalent performance Less expensive instrument and plates required
The AlphaLISA® assay is a homogeneous immunoassay alternative to classical ELISA. AlphaLISA assays were originally utilized to detect analytesin cell cultures upernatants or serum/plasma samples.